Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, pp.5446-5456, 2008. ,
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-2760, 2018. ,
The immunological profile of B-Cell discorders and proposal of a scoring system for the diagnosis of CLL, 1994. ,
Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8 (CD79b), 1997. ,
Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia: Are They the Same Disease?, The Cancer Journal, vol.18, pp.396-403, 2012. ,
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia, N Engl J Med, vol.359, pp.575-583, 2008. ,
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia, N Engl J Med, vol.360, pp.659-667, 2009. ,
Cancer incidence in France over the 1980-2012 period: Hematological malignancies. Revue d'Épidémiologie et de Santé Publique, vol.64, pp.103-112, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01511580
SFH Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia (CLL), Hématologie, vol.19, pp.4-9, 2012. ,
Improved survival in chronic lymphocytic leukemia in the past decade: a populationbased study including 11,179 patients diagnosed between 1973-2003 in Sweden, Haematologica, vol.94, pp.1259-1265, 2009. ,
The clinical significance of patients' sex in chronic lymphocytic leukemia, Haematologica, vol.99, pp.1088-1094, 2014. ,
Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France, Int. J. Cancer, vol.132, pp.2378-2387, 2013. ,
La leucémie lymphoïde chronique : mise au point, La Presse Médicale, vol.48, pp.807-815, 2019. ,
Familial chronic lymphocytic leukaemia: a survey and review of published studies, Br J Haematol, vol.109, pp.794-799, 2000. ,
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database, Blood, vol.104, pp.1850-1854, 2004. ,
Familial predisposition and genetic risk factors for lymphoma, Blood, vol.126, pp.2265-2273, 2015. ,
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion, Blood, vol.100, pp.2289-2290, 2002. ,
A New Prognostic Classification of Chronic Lymphocytic Leukemia Derived from a Multivariate Survival Analysis, 1981. ,
Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia, Leukemia Research, vol.34, pp.892-898, 2010. ,
Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group, Journal of Clinical Pathology, vol.42, pp.567-584, 1989. ,
Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12, British Journal of Haematology, vol.98, pp.934-939, 1997. ,
Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases, British Journal of Haematology, vol.97, pp.383-391, 1997. ,
The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial, Br J Haematol, vol.174, pp.767-775, 2016. ,
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project: ERIC/ESCCA Consensus: Reproducible CLL diagnosis by flow cytometry, Cytometry, vol.94, pp.121-128, 2018. ,
CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry: CD200 Role in the Diagnosis of B-Cell Neoplasms, 2013. ,
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proceedings of the National Academy of Sciences 105, pp.3047-3052, 2008. ,
Autoimmune cytopenias in chronic lymphocytic leukemia: Autoimmune Cytopenias in CLL, Am. J. Hematol, vol.89, pp.1055-1062, 2014. ,
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia, Curr Hematol Malig Rep, vol.12, pp.29-38, 2017. ,
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia, JCO, vol.16, pp.1885-1889, 1998. ,
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia, Am. J. Hematol, vol.87, pp.936-937, 2012. ,
Perturbation of the normal immune system in patients with CLL, Blood, vol.126, pp.573-581, 2015. ,
Chronic lymphocytic leukaemia, Nat Rev Dis Primers, vol.3, p.16096, 2017. ,
Controlled Clinical Trial Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia*. Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic Leukemia, N Engl J Med, vol.319, pp.902-907, 1988. ,
Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?, J Clin Immunol, vol.34, pp.277-282, 2014. ,
Biology and treatment of Richter syndrome, Blood, vol.131, pp.2761-2772, 2018. ,
Richter syndrome: pathogenesis and management, Seminars in Oncology, vol.43, pp.311-319, 2016. ,
Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review, Histopathology, vol.69, pp.1066-1076, 2016. ,
PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness, 2017. ,
IgVH Mutational Status and Clonality Analysis of Richter?s Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution, The American Journal of Surgical Pathology, vol.31, pp.1605-1614, 2007. ,
Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion, Human Pathology, vol.55, pp.108-116, 2016. ,
Solid tumors after chronic lymphocytic leukemia, Blood, vol.98, 1979. ,
Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype, JCO, vol.28, pp.4935-4944, 2010. ,
Chronic lymphocytic leukaemia, Critical Reviews in Oncology/Hematology, vol.104, pp.169-182, 2016. ,
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-2760, 2018. ,
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, N Engl J Med, vol.343, pp.1910-1916, 2000. ,
Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant, Leukemia, vol.26, pp.170-172, 2012. ,
Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data: Translocations and karyotype complexity in CLL, Am. J. Hematol, vol.89, pp.249-255, 2014. ,
Research Initiative on CLL (ERIC) et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations, Leukemia, vol.24, pp.2072-2079, 2010. ,
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience, Blood, vol.114, pp.957-964, 2009. ,
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results: 17p-CLL, Br J Haematol, vol.157, pp.67-74, 2012. ,
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, Blood, vol.112, pp.3322-3329, 2008. ,
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia, JCO, vol.28, pp.4473-4479, 2010. ,
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, vol.123, pp.2139-2147, 2014. ,
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia, Oncotarget, vol.9, 2018. ,
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping, Leukemia, vol.21, pp.2442-2451, 2007. ,
Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks, Clinical Cancer Research, vol.16, pp.835-847, 2010. ,
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia, 1999. ,
& Klaus Dittmar. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia, 1999. ,
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment, Leukemia, vol.20, pp.1159-1161, 2006. ,
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia, 2002. ,
Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia, Blood, vol.99, pp.2262-2264, 2002. ,
Human CD38: a (r)evolutionary story of enzymes and receptors, Leukemia Research, vol.25, pp.1-12, 2001. ,
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia, Blood, vol.98, pp.181-186, 2001. ,
The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience, Br J Haematol, vol.130, pp.549-557, 2005. ,
ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia, N Engl J Med, vol.348, pp.1764-1775, 2003. ,
CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia, JCO, vol.32, pp.897-904, 2014. ,
Clinical and Laboratory Prognostic Indicators in Chronic Lymphocytic Leukemia, Cancer Control, vol.19, pp.18-25, 2012. ,
Predictive value of 2-microglobulin ( 2-m) levels in chronic lymphocytic leukemia since Binet A stages, Haematologica, vol.94, pp.887-888, 2009. ,
, Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, vol.24, pp.174-180, 2009.
Beta 2 -microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate, British Journal of Haematology, vol.145, pp.801-805, 2009. ,
, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a metaanalysis of individual patient data, The Lancet Oncology, vol.17, pp.779-790, 2016.
Thymidine kinase isoenzymes in chronic lymphocytic leukaemia, Br J Haematol, vol.49, pp.479-481, 1981. ,
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL, Leukemia, vol.17, pp.133-137, 2003. ,
Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors, Int J Hematol, vol.90, pp.205-211, 2009. ,
Serum Thymidine Kinase Activity: Analytical Performance, Age-Related Reference Ranges and Validation in Chronic Lymphocytic Leukemia, PLoS ONE, vol.9, p.91647, 2014. ,
Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and ?2-microglobulin in B-cell chronic lymphocytic leukemia, European Journal of Haematology, vol.62, pp.117-122, 2009. ,
Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia, 1996. ,
Soluble CD23 measurement by CBA: A convenient and reliable quantification method in Chronic Lymphocytic Leukemia, 2013. ,
Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia, 1987. ,
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance, Br J Haematol, vol.62, pp.567-575, 1986. ,
Clinical staging of chronic lymphocytic leukemia, 1975. ,
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia, Blood, vol.121, pp.1403-1412, 2013. ,
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients, Blood, vol.128, pp.2093-2095, 2016. ,
The CLL-IPI applied in a population-based cohort, Blood, vol.128, pp.2181-2183, 2016. ,
Chronic lymphocytic leukemia treatment algorithm, Blood Cancer Journal, vol.8, p.93, 2018. ,
Chlorambucil in Indolent Chronic Lymphocytic Leukemia, N Engl J Med, vol.338, pp.1506-1514, 1998. ,
, Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials, Journal of the National Cancer Institute, vol.91, pp.861-868, 1999.
Comorbidity and functional status are independent in older cancer patients, JCO, vol.16, pp.1582-1587, 1998. ,
Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.59, pp.2258-2260, 2018. ,
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment, Am J Hematol, vol.94, pp.1266-1287, 2019. ,
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia, JCO, vol.30, pp.2820-2822, 2012. ,
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia, vol.21, pp.956-964, 2007. ,
, A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study, on behalf of ERIC (European Research Initiative on CLL), vol.30, pp.929-936, 2016.
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL, Blood, vol.127, pp.279-286, 2016. ,
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? Front, Oncol, vol.9, p.689, 2019. ,
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL, CLL, vol.27, pp.142-149, 2013. ,
Maladie résiduelle minime dans la leucémie lymphoïde chronique : un enjeu restant d'actualité, Bulletin du Cancer, vol.105, pp.1042-1051, 2018. ,
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis, Leukemia, vol.23, pp.2007-2017, 2009. ,
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR, Br J Haematol, vol.166, pp.360-368, 2014. ,
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment, Proceedings of the National Academy of Sciences, vol.108, pp.21194-21199, 2011. ,
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine, HemaSphere, vol.3, p.287, 2019. ,
Minimal residual disease is an independent predictor for 10-year survival in CLL, Blood, vol.128, pp.2770-2773, 2016. ,
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group, JCO, vol.34, pp.3758-3765, 2016. ,
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL, Blood, vol.123, pp.3727-3732, 2014. ,
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial, Blood, vol.130, pp.1477-1480, 2017. ,
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial, Blood, vol.121, pp.3284-3288, 2013. ,
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome, Cancer, vol.117, pp.4679-4688, 2011. ,
Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group, JCO, vol.21, pp.2747-2753, 2003. ,
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning, JCO, vol.26, pp.4912-4920, 2008. ,
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: Long-term prospective multicenter study, Experimental Hematology, vol.41, pp.127-133, 2013. ,
, on behalf of the Chronic Leukemia Working Party of the EBMT et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus, Leukemia, vol.21, pp.12-17, 2007.
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?, Blood, vol.124, pp.3841-3849, 2014. ,
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation, Bone Marrow Transplant, vol.51, pp.793-798, 2016. ,
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease, J. Clin. Invest, vol.124, pp.4867-4876, 2014. ,
Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Annales de biologie clinique, vol.74, pp.561-567, 2016. ,
Functions and epigenetic aspects of miR-15/16: Possible future cancer therapeutics, Gene Reports, vol.12, pp.149-164, 2018. ,
miR-15 and miR-16 induce apoptosis by targeting BCL2, Proceedings of the National Academy of Sciences, vol.102, pp.13944-13949, 2005. ,
Nonlinear partial differential equations and applications: Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proceedings of the National Academy of Sciences, vol.99, pp.15524-15529, 2002. ,
The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia, Cancer Cell, vol.17, pp.28-40, 2010. ,
Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders, Proceedings of the National Academy of Sciences, vol.93, pp.11837-11841, 1996. ,
Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia, The Lancet, vol.353, pp.26-29, 1999. ,
Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B, European Journal of Cancer, vol.43, pp.1328-1335, 2007. ,
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial, Haematologica, vol.99, pp.736-742, 2014. ,
Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications, Cancer Genetics and Cytogenetics, vol.94, pp.27-35, 1997. ,
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities, Cancer Cell, vol.25, pp.304-317, 2014. ,
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, pp.101-105, 2011. ,
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia, N Engl J Med, vol.365, pp.2497-2506, 2011. ,
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation, Leukemia, vol.30, pp.182-189, 2016. ,
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, vol.44, pp.47-52, 2012. ,
Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations, Blood, vol.128, pp.970-970, 2016. ,
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations, Blood, vol.127, pp.1007-1016, 2016. ,
Non-coding recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.526, pp.519-524, 2015. ,
Somatic mutation as a mechanism of Wnt/?-catenin pathway activation in CLL, Blood, vol.124, pp.1089-1098, 2014. ,
Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers, Best Practice & Research Clinical Haematology, vol.29, pp.79-89, 2016. ,
The clinical implications of gene mutations in chronic lymphocytic leukaemia, Br J Cancer, vol.114, pp.849-854, 2016. ,
Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact, Seminars in Cancer Biology, vol.51, pp.1-11, 2018. ,
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia, Nat Genet, vol.48, pp.253-264, 2016. ,
Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia, Cancer Cell, vol.26, pp.813-825, 2014. ,
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia, Cancer Discovery, vol.4, pp.348-361, 2014. ,
Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2, Epigenetics, vol.11, pp.449-455, 2016. ,
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia, Oncotarget, vol.7, 2016. ,
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia, N Engl J Med, vol.353, pp.1793-1801, 2005. ,
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia, Proc Natl Acad Sci, vol.112, pp.2169-2174, 2015. ,
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression, Proceedings of the National Academy of Sciences, vol.99, pp.6955-6960, 2002. ,
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia, Blood, vol.124, pp.546-554, 2014. ,
Checkpoints that control B cell development, J. Clin. Invest, vol.125, pp.2203-2210, 2015. ,
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies, Nat Rev Immunol, vol.13, pp.578-591, 2013. ,
Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future, Clinical Therapeutics, vol.35, pp.1258-1270, 2013. ,
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment, Biochimica et Biophysica Acta (BBA) -Molecular Cell Research, vol.1863, pp.401-413, 2016. ,
The Cytoskeleton Coordinates the Early Events of B-cell Activation, Cold Spring Harbor Perspectives in Biology, vol.3, pp.2360-002360, 2011. ,
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy, Haematologica, vol.99, pp.1138-1148, 2014. ,
The lymph node microenvironment promotes B-cell receptor signaling, NF-?B activation, and tumor proliferation in chronic lymphocytic leukemia, Blood, vol.117, pp.563-574, 2011. ,
Signalisation du BCR et rôle du microenvironnement dans la leucémie lymphoïde chronique, 2014. ,
Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression, Cancer Res, vol.66, pp.7158-7166, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-02060842
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia, Blood, vol.120, pp.356-365, 2012. ,
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies, Seminars in Cancer Biology, vol.24, pp.71-81, 2014. ,
Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease, Cancer Research, vol.69, pp.6387-6395, 2009. ,
HIF-1? is over-expressed in leukemic cells from TP53 -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia, Haematologica, vol.105, pp.1042-1054, 2020. ,
HIF-1?: a potential treatment target in chronic lymphocytic leukemia, Haematologica, vol.105, pp.856-858, 2020. ,
Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies, 2014. ,
Apoptosis inducers in chronic lymphocytic leukemia, Oncotarget, vol.5, 2014. ,
Reprogramming cell death: BCL2 family inhibition in hematological malignancies, Immunology Letters, vol.155, pp.36-39, 2013. ,
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL), Leukemia, vol.16, pp.1045-1052, 2002. ,
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia, Immunology, vol.114, pp.441-449, 2005. ,
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia, 1993. ,
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia, Haematologica, vol.101, pp.77-85, 2016. ,
Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis, Cancer Letters, vol.317, pp.144-149, 2012. ,
Cancer stem cells, cancer cell plasticity and radiation therapy, Seminars in Cancer Biology, vol.31, pp.28-35, 2015. ,
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients, Blood, vol.98, pp.2319-2325, 2001. ,
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia, JCO, vol.27, pp.4378-4384, 2009. ,
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia, Ann Hematol, vol.92, pp.653-660, 2013. ,
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia, 1999. ,
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, The Lancet, vol.376, pp.1164-1174, 2010. ,
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, pp.208-215, 2016. ,
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial, The Lancet Oncology, vol.17, pp.928-942, 2016. ,
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, J Immunol, vol.177, pp.362-371, 2006. ,
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia, JCO, vol.28, pp.1749-1755, 2010. ,
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial, The Lancet, vol.385, pp.1873-1883, 2015. ,
Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991, 2014. ,
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study, Blood, vol.126, pp.842-850, 2015. ,
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, vol.115, pp.4393-4402, 2010. ,
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions, N Engl J Med, vol.370, pp.1101-1110, 2014. ,
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data, Therapeutic Advances in Hematology, vol.7, pp.222-230, 2016. ,
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies, 2010. ,
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab, Br J Haematol, vol.177, pp.243-253, 2017. ,
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, Blood, vol.134, pp.1811-1820, 2019. ,
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial, Br J Haematol, vol.176, pp.412-420, 2017. ,
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood, vol.103, pp.3278-3281, 2004. ,
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia, JCO, vol.25, pp.5616-5623, 2007. ,
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial, Blood, vol.119, pp.5104-5110, 2012. ,
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies, JCO, vol.23, pp.6719-6729, 2005. ,
, Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox, vol.17, pp.6398-6405, 2011.
Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results, Blood, vol.108, pp.32-32, 2006. ,
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells, Blood, vol.116, pp.2554-2558, 2010. ,
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia, Br J Haematol, vol.176, pp.618-628, 2017. ,
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment, Blood Cancer Journal, vol.6, pp.496-496, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02348641
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, The Lancet Oncology, vol.16, pp.169-176, 2015. ,
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.369, pp.32-42, 2013. ,
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, N Engl J Med, vol.373, pp.2425-2437, 2015. ,
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial, The Lancet Oncology, vol.20, pp.43-56, 2019. ,
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, N Engl J Med, vol.371, pp.213-223, 2014. ,
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study, The Lancet Oncology, vol.17, pp.200-211, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01885700
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia, N Engl J Med, vol.381, pp.432-443, 2019. ,
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia, Blood, vol.133, pp.1011-1019, 2019. ,
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL, N Engl J Med, vol.379, pp.2517-2528, 2018. ,
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, N Engl J Med, vol.370, pp.2286-2294, 2014. ,
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, pp.323-332, 2016. ,
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on -and off -target inhibition, Biochimica et Biophysica Acta (BBA) -General Subjects, vol.1864, p.129531, 2020. ,
A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL), 2013. ,
Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia, Clin Cancer Res clincanres, vol.3504, 2019. ,
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory Bcell NHL and CLL, Oncotarget, vol.9, 2018. ,
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110?, for relapsed/refractory chronic lymphocytic leukemia, Blood, vol.123, pp.3390-3397, 2014. ,
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.370, pp.997-1007, 2014. ,
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, doubleblind, placebo-controlled trial, The Lancet Oncology, vol.18, pp.297-311, 2017. ,
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL, Blood, vol.132, pp.2446-2455, 2018. ,
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma, Clinical Cancer Research, vol.21, pp.3160-3169, 2015. ,
, Lunenburg Lymphoma Phase I/II Consortium et al. Final results of a phase 1b study of the safety and efficacy of the PI3K? inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies, Blood Cancer Journal, vol.8, p.16, 2018.
A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND, vol.216, 2017. ,
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies, Br J Haematol, vol.175, pp.55-65, 2016. ,
A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia, Blood, vol.118, pp.2858-2858, 2011. ,
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, Clinical Cancer Research, vol.17, pp.2977-2986, 2011. ,
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia, Blood, vol.115, pp.2578-2585, 2010. ,
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study, Leukemia & Lymphoma, vol.60, pp.1972-1977, 2019. ,
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment, Oncotarget, vol.8, 2017. ,
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.60, pp.3461-3469, 2019. ,
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway, Oncotarget, vol.7, 2016. ,
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization, Blood, vol.123, pp.1032-1039, 2014. ,
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia, Haematologica, vol.104, pp.2053-2060, 2019. ,
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia, Cancer Immunol Immunother, vol.64, pp.665-676, 2015. ,
Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression, Cancer Gene Ther, vol.19, pp.336-344, 2012. ,
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.51, pp.228-235, 2010. ,
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.53, pp.2136-2142, 2012. ,
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib, Blood Advances, vol.3, pp.447-460, 2019. ,
Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia, Clinical Cancer Research, vol.18, pp.3812-3821, 2012. ,
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation, Blood, vol.109, pp.4810-4815, 2007. ,
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors, j. immunotherapy cancer, vol.1, pp.2051-1426, 2013. ,
Expression and Function of the Ror-Family Receptor Tyrosine Kinases During Development: Lessons from Genetic Analyses of Nematodes, Mice, and Humans, Journal of Receptors and Signal Transduction, vol.23, pp.1-15, 2003. ,
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia, Leukemia Research, vol.35, pp.1390-1394, 2011. ,
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proceedings of the National Academy of Sciences 105, pp.3047-3052, 2008. ,
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia, Blood, vol.128, pp.2931-2940, 2016. ,
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia, Cell Stem Cell, vol.22, pp.951-959, 2018. ,
Mitochondria control of cell death induced by anti-HLA-DR antibodies, Leukemia, vol.17, pp.1357-1365, 2003. ,
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia, Leukemia & Lymphoma, vol.50, pp.1958-1963, 2009. ,
Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia, JCO, vol.23, pp.6607-6607, 2005. ,
Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, Cutaneous T Cell Lymphoma. Blood, vol.132, pp.2903-2903, 2018. ,
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis, Proceedings of the National Academy of Sciences, vol.104, pp.19512-19517, 2007. ,
Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms, Expert Opinion on Investigational Drugs, vol.21, pp.363-373, 2012. ,
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.2826-2833, 2015. ,
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, pp.311-322, 2016. ,
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, The Lancet Oncology, vol.17, pp.768-778, 2016. ,
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia, N Engl J Med, vol.378, pp.1107-1120, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02348612
Venetoclax and obinutuzumab in chronic lymphocytic leukemia, Blood, vol.129, pp.2702-2705, 2017. ,
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions, N Engl J Med, vol.380, pp.2225-2236, 2019. ,
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study, JCO, vol.37, pp.2722-2729, 2019. ,
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth, Oncotarget, vol.9, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01807731
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, JCO, vol.30, pp.488-496, 2012. ,
Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL), Blood, vol.118, pp.3904-3904, 2011. ,
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.2826-2833, 2015. ,
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.56, pp.3336-3342, 2015. ,
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia, Blood, vol.113, pp.299-305, 2009. ,
A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens, Blood, vol.110, pp.3119-3119, 2007. ,
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs, Pharmacological Research, vol.107, pp.249-275, 2016. ,
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors, Cancers, vol.7, pp.179-237, 2015. ,
Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review, New J. Chem, vol.42, pp.18500-18507, 2018. ,
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia, Leukemia, vol.29, pp.1524-1529, 2015. ,
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients, Cancer Chemother Pharmacol, vol.74, pp.1057-1064, 2014. ,
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent antileukemic properties, Leukemia, vol.26, pp.236-243, 2012. ,
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia, Blood, vol.113, pp.4637-4645, 2009. ,
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia, Seminars in Oncology, vol.43, pp.265-273, 2016. ,
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease, JCO, vol.27, pp.6012-6018, 2009. ,
Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia, Blood, vol.129, pp.1876-1878, 2017. ,
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells, Blood, vol.111, pp.846-855, 2008. ,
Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1), Mol Med, vol.18, pp.19-28, 2012. ,
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study: A KT I NHIBITOR MK -2206 PLUS BR IN R ELAPSED CLL, Am J Hematol, vol.92, pp.759-763, 2017. ,
Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL), Blood, vol.116, pp.1842-1842, 2010. ,
Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity, Clinical Cancer Research, vol.13, pp.2144-2150, 2007. ,
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen, JCO, vol.27, pp.5208-5212, 2009. ,
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia, Blood, vol.121, pp.136-147, 2013. ,
Oblimersen for the treatment of patients with chronic lymphocytic leukemia, 2007. ,
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia, Blood, vol.119, pp.1162-1172, 2012. ,
Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa, Leukemia, vol.21, pp.1773-1782, 2007. ,
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia, Blood, vol.105, pp.959-967, 2004. ,
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia, British Journal of Haematology, vol.147, pp.507-514, 2009. ,
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study, Haematologica, vol.102, pp.903-909, 2017. ,
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib, Clin Cancer Res, vol.23, pp.3084-3096, 2017. ,
The 26S proteasome complex: An attractive target for cancer therapy, Biochimica et Biophysica Acta (BBA) -Reviews on Cancer, vol.1825, pp.64-76, 2012. ,
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib, Oncogene, vol.27, pp.1189-1197, 2008. ,
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells, Haematologica, vol.95, pp.1510-1518, 2010. ,
Phase II study of single-agent bortezomib for the treatment of patients with fludarabinerefractory B-cell chronic lymphocytic leukemia, Cancer, vol.107, pp.916-924, 2006. ,
The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-B Response in Chronic Lymphocytic Leukemia Cells, Clinical Cancer Research, vol.19, pp.2406-2419, 2013. ,
Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy, Clinical Cancer Research, vol.18, pp.5639-5649, 2012. ,
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia, Blood, vol.125, pp.407-410, 2015. ,
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma, Leukemia & Lymphoma, vol.56, pp.2834-2840, 2015. ,
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia, Oncotarget, vol.6, 2015. ,
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo, Blood, vol.116, pp.4578-4587, 2010. ,
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma, Br J Haematol, vol.182, pp.429-433, 2018. ,
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells, Haematologica, vol.104, pp.2429-2442, 2019. ,
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia, Blood, vol.106, pp.2506-2512, 2005. ,
Targeted induction of apoptosis for cancer therapy: current progress and prospects, Trends in Molecular Medicine, vol.12, pp.382-393, 2006. ,
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics, Leukemia & Lymphoma, vol.51, pp.85-88, 2010. ,
Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia, JCO, vol.25, pp.5047-5047, 2007. ,
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study, The Lancet Haematology, vol.4, pp.475-486, 2017. ,
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, JCO, vol.31, pp.584-591, 2013. ,
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL, Leukemia, vol.24, pp.1972-1975, 2010. ,
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL, Blood, vol.129, pp.3419-3427, 2017. ,
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, N Engl J Med, vol.365, pp.725-733, 2011. ,
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib, JCO, vol.35, pp.3010-3020, 2017. ,
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia, Br J Haematol, vol.141, pp.607-614, 2008. ,
Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy, J Clin Immunol, vol.32, pp.632-646, 2012. ,
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, 1999. ,
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia, OncoImmunology, vol.5, p.1226720, 2016. ,
CD200:CD200R-Mediated Regulation of Immunity, ISRN Immunology, vol.2012, pp.1-18, 2012. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-264, 2012. ,
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint, CD200. j. immunotherapy cancer, vol.7, p.227, 2019. ,
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000. ,
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy, Blood, vol.118, pp.2530-2540, 2011. ,
A platform for phenotypic discovery of therapeutic antibodies and targets applied on, Chronic Lymphocytic Leukemia. npj Precision Onc, vol.2, p.18, 2018. ,
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia, Leukemia, vol.21, pp.53-60, 2007. ,
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.53, pp.211-217, 2012. ,
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells, Blood, vol.115, pp.5041-5052, 2010. ,
A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia, Leukemia, vol.24, pp.222-226, 2010. ,
Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity, J Immunol, vol.176, pp.3830-3839, 2006. ,
Reactive Oxygen Species (ROS)--Induced genetic and epigenetic alterations in human carcinogenesis, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.711, pp.167-173, 2011. ,
Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias, Clinica Chimica Acta, vol.293, pp.53-62, 2000. ,
ROS stress in cancer cells and therapeutic implications, Drug Resistance Updates, vol.7, pp.97-110, 2004. ,
Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic lerkenia, Free Radical Biology and Medicine, vol.30, pp.1286-1292, 2001. ,
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol ?, EMBO J, vol.24, pp.3482-3492, 2005. ,
The antioxidant function of the p53 tumor suppressor, Nat Med, vol.11, pp.1306-1313, 2005. ,
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redoxmediated mechanism, Blood, vol.112, pp.1912-1922, 2008. ,
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat Rev Drug Discov, vol.8, pp.579-591, 2009. ,
Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROSmediated mechanism, Oncotarget, vol.7, 2016. ,
Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.26, pp.5541-5552, 2007. ,
Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics, Trends in Pharmacological Sciences, vol.40, pp.774-789, 2019. ,
Role of Aldehyde Dehydrogenases in Physiopathological Processes, Chem. Res. Toxicol, vol.32, pp.405-420, 2019. ,
Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily, Expert Opinion on Drug Metabolism & Toxicology, vol.4, pp.697-720, 2008. ,
The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells, Stem Cell Rev and Rep, vol.7, pp.292-306, 2011. ,
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide, Cancer Chemother Pharmacol, vol.59, pp.137-137, 2006. ,
Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer, Immunology, vol.156, pp.47-55, 2019. ,
Anticancer metal drugs and immunogenic cell death, Journal of Inorganic Biochemistry, vol.165, pp.71-79, 2016. ,
Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application, Pharmacol Rev, vol.64, pp.520-539, 2012. ,
Aldehyde dehydrogenase inhibitors: ?,?-Acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture, European Journal of Medicinal Chemistry, vol.43, pp.906-916, 2008. ,
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors, Blood Cancer Journal, vol.6, pp.469-469, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02324893
The effect of a novel irreversible inhibitor of aldehyde dehydrogenases 1 and 3 on tumour cell growth and death, Chemico-Biological Interactions, vol.130, pp.209-218, 2001. ,